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Immunodepletion of clinical ﬂuids to overcome the dominance by a few very abundant
proteins has been explored but studies are few, commonly examining only limited aspects
with one analytical platform. We have systematically compared immunodepletion of 6, 14, or
20 proteins using serum from renal transplant patients, analysing reproducibility, depth of
coverage, efﬁciency, and speciﬁcity using 2-D DIGE (‘top-down’) and LC-MS/MS (‘bottom-
up’). A progressive increase in protein number (Z2 unique peptides) was found from 159 in
unfractionated serum to 301 following 20 protein depletion using a relatively high-
throughput 1-D-LC-MS/MS approach, including known biomarkers and moderate–lower
abundance proteins such as NGAL and cytokine/growth factor receptors. On the contrary,
readout by 2-D DIGE demonstrated good reproducibility of immunodepletion, but additional
proteins seen tended to be isoforms of existing proteins. Depletion of 14 or 20 proteins
followed by LC-MS/MS showed excellent reproducibility of proteins detected and a signiﬁcant
overlap between columns. Using label-free analysis, greater run-to-run variability was seen
with the Prot20 column compared with the MARS14 column (median %CVs of 30.9 versus
18.2%, respectively) and a corresponding wider precision proﬁle for the Prot20. These results
illustrate the potential of immunodepletion followed by 1-D nano-LC-LTQ Orbitrap Velos
analysis in a moderate through-put biomarker discovery process.
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1 Introduction
Biomarkers are increasingly important in the drive to indi-
vidualise healthcare. Remarkable strides in proteomic tech-
nologies have been made but the results for clinical ﬂuid-
based discovery studies are disappointing with few emer-
ging novel markers with strong enough clinical perfor-
mance to suggest that they will contribute to changing
clinical practice. The existence of such powerful markers
remains a real possibility but they may occur in relatively
low abundance. Hence, efforts to study the lower abundance
plasma and serum proteome in comparative analyses are
central to progress if such studies are to realise their
Abbreviations: IAA, iodoacetamide; IL, interleukin; IPA, Ingenu-
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biomarkers as they are minimally invasive and potentially
contain proteins and peptides shed directly by diseased
tissues as well as those reﬂecting systemic effects of the
disease process. However, using serum/plasma for
biomarker discovery studies is challenging due to the wide
dynamic range of protein abundances (over ten orders of
magnitude) and the fact that 22 proteins make up around
99% of the total protein mass [1].
To overcome these various issues, fractionation approa-
ches have been employed. Extensive fractionation combin-
ing immunoafﬁnity subtraction of the most abundant
proteins with subsequent chemical fractionation based on
cysteinyl peptide and N-glycopeptide selective captures, and
analysis with 2-D LC-tandem mass spectrometry (LC-MS/
MS), resulted in the identiﬁcation of 1494 proteins in a
trauma patient plasma sample including 78 cytokines/
cytokine receptors [2]. Similarly, targeting glycosylated
serum proteins using hydrazide chemistry with stable
isotope labelling of glycopeptides and MS/MS [3] has
enabled the identiﬁcation of lower abundance proteins
including carboxypeptidase N and interferon (a and b)
receptor 2 [4]. However, such extensive and time-consuming
fractionation is not easily compatible with biomarker
discovery experiments where comparative quantitative
analysis of multiple samples is required. A relatively simple
approach which has been used either singly or as the ﬁrst
step in these more complex fractionation series is the
removal of the most abundant proteins by immunodeple-
tion [5]. However, little systematic investigation has been
carried out in terms of the relative beneﬁts of removing
different numbers of abundant proteins in terms of the
depth of coverage achieved in relatively rapid processing, the
speciﬁcity, reproducibility, and the ease of use/compatibility
of the approaches with subsequent proteomic analyses. A
range of commercially produced LC columns are now
available for immunodepletion including the Multiple Afﬁ-
nity Removal System (MARS) series of columns variably
removing 6, 7, or 14 abundant proteins (Agilent, CA, USA)
and the ProteoPrep20 which removes 20 proteins (Sigma-
Aldrich, UK).
The MARS6 column has been most extensively used in
comparative studies [6–9]. Good run-to-run variability and
higher total numbers of peptide/protein identiﬁcations have
been achieved, e.g. 138 protein identiﬁcations with at least
two peptides for MARS6-depleted serum/plasma compared
with o100 for six other strategies employing various
biochemical enrichment methods when assessed by LC-MS/
MS or similar approaches [6, 8]. A recent assessment of
depletion with either MARS14 or MARS6 in healthy
volunteer plasma samples concluded a similar 25% increase
in identiﬁcation was seen with either column, with 23
moderate- to low-abundance proteins detected in depleted
samples (e.g. intercellular adhesion molecule 1, macrophage
CSF receptor 1) [10]. Reported disadvantages of immuno-
depletion columns include variable depletion efﬁciency
[8, 11] between proteins and concomitant loss of non-
targeted proteins [10, 12]. Examination of the effects of
removing 20 proteins is limited, but a 2-D PAGE-based
study including MARS6, Seppro MIXED12-LC20, and
ProteoPrep20 spin columns revealed >1200 gel features with
6 or 12 protein depletion though only 1024 with 20 depletion
which was only a minimal improvement from depletion of
just albumin and IgG [13]. A limited analysis of the removal
of 1, 6, 12, or 20 proteins with MARS6, IgY-12 high-capacity
spin column (Beckman Coulter, High Wycombe, UK) and
ProteoPrep20 spin column [14] showed some additional
depth of coverage, such as the detection of factor H
complement protein only after depletion of 12 or 20
proteins.
We report here the results of a systematic analysis of the
effects of removing either 6, 14, or 20 proteins compared
with whole serum alone, comparing depth of coverage,
reproducibility, ease of use, and speciﬁcity. This was
achieved using pooled serum samples from patients post-
renal transplantation which are likely to contain a wider
range of proteins than healthy control samples, which have
been often used by other studies [10, 13]. Importantly, both
2-D DIGE (top-down) and parallel LC-MS/MS analysis
(bottom-up) were used as downstream readouts. The results
of this study provide important insights into the use of
immunodepletion in relatively simple serum-based
biomarker discovery pipelines.
2 Materials and methods
2.1 Materials
MARS6 Hu6HC 4.6100mm column, MARS14 Hu14
4.6100mm column, and MARS buffers A and B were
obtained from Agilent (West Lothian, UK). The Prot20
depletion column and the ProteoSilver kit were obtained
from Sigma-Aldrich and 15mL capacity, 10kDa molecular
weight cut-off (MWCO) spin-ﬁlter units were obtained from
Millipore (Watford, UK). Corning Spin-X centrifuge tubes,
0.2mm pore size were obtained from Corning (Amsterdam,
The Netherlands). Bradford reagent was obtained from
Bio-Rad (Herts, UK). ZEBA-spin desalt columns, 2mL
size, were obtained from Pierce (Northumberland, UK).
Cy-ﬂuorescent dyes, IPG-strips, and bovine serum albumin
standard were obtained from GE-Healthcare (Bucks, UK).
Sequencing-grade trpysin was obtained from Promega
(Southampton, UK). All other chemicals were obtained from
Sigma-Aldrich and were of analytical grade or above.
2.2 Samples
A pooled serum sample was prepared by combining serum
samples from 17 patients (ten male and seven female; age
range, 16–68 years) at days 1–3 post-renal transplant. All
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ethics approval. In each case, venous blood samples had
been collected into 9mL Z-serum clot activator tubes
(Greiner Bio-One, UK), left to clot for minimum 45min
before being centrifuged at 2000g for 10min at room
temperature. Serum was aliquotted and then stored at
801C until use. The protein concentration of the starting
pooled serum sample and all bound/unbound fractions after
later immunodepletion were determined using the modiﬁed
Bradford method (Bio-Rad) using a bovine serum albumin
standard (GE Healthcare). An overview of the study
elements is shown in Fig. 1.
2.3 Depletion of high-abundance proteins
The intended depletions of the three tested columns are
albumin, IgG, IgA, transferrin, ﬁbrinogen, a-1-antitrypsin,
and haptoglobin (all columns) with additionally IgM, a-2-
macroglobulin, a-1-acid glycoprotein, apolipoprotein A-I,
apolipoprotein A-II, complement C3 and transthyretin
(MARS14 and Prot20), and IgD, ceruloplasmin, apolipo-
protein B, complement C1q, complement C4, and plasmi-
nogen (Prot20). The MARS columns were run on an Agilent
1200 series HPLC, with UV absorbance detector set at
214nm, with proprietary buffers. Serum was ﬁltered
through 0.22mm Spin-X ﬁlters and diluted at 1:4 with buffer
A before injection (320mL diluted serum for MARS6 and
160mL for MARS14). Running conditions were as follows:
MARS6 – max. pressure, 120MPa, 100% buffer A at 0.5mL/
min, 0–13min, 100%, buffer B at 1.0mL/min, 13–20min,
100% buffer A at 1.0mL/min, 20–30min; MARS14 – max.
pressure 60MPa, 100% buffer A at 0.125mL/min,
0–21min, 100% buffer A at 1.0mL/min, 21–23min, 100%
buffer B at 1.0mL/min, 23–30min, 100% buffer A at
1.0mL/min, 30–41min. In both cases, fractions were
collected at 1-min intervals at 41C throughout. The Prot20
column was run using an AKTA-FPLC system with a
280nm UV absorbance detector (GE-Healthcare). The
column was equilibrated with Buffer 1 (20mM sodium
phosphate, pH 7.4, 0.15M NaCl) for at least two column
volumes. Buffer 2 was 0.1M glycine, pH 2.5, 0.1%-b-D-
octylglucopyranoside. For the Prot20 column, 100mL neat,
ﬁltered serum was injected per run with conditions as
Figure 1. Schematic overview of the experimental approach. (A) Pooled serum (from 17 renal transplant patients) either unfractionated or
following depletion of 6, 14, or 20 proteins was compared using 1-D PAGE, 2-D DIGE, and LC-MS/MS to assess reproducibility, efﬁciency,
speciﬁcity, and depth of coverage; (B) Design of the subsequent more detailed analysis of the reproducibility of the depletion process (14
or 20 proteins) combined with LC-MS/MS. Repeat analysis of one sample replicate in each case was used to provide an indication of the
reproducibility of the LC-MS/MS analysis. In each case, triplicate injections were carried out for all replicates.
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min, 0–22mL, 100% Buffer 2, 3.0mL/min, 22–52mL, 100%
Buffer 1, 3.0mL/min, 52–82mL. In all, 1mL fraction was
collected at 41C throughout.
For each run, fractions containing the depleted serum
(peak 1) following removal of the high-abundance proteins
were pooled and frozen at 801C as were fractions
containing the bound high-abundance proteins (peak 2).
For peak 1, these were typically fractions 4–7 (MARS6,
2mL), 9–16 (MARS14, 1mL), and 10–20 (Prot20,
11mL). For peak 2, these were typically fractions 14–16
(MARS6, 3mL), 23–25 (MARS14, 3mL), and 26–43
(Prot20, 18mL). After each run, the columns were re-equi-
librated (Buffer A, 10min, 1mL/min for MARS6 and
MARS14; Buffer 1, 10min, 1mL/min for Prot20). At least
one blank run was performed between each serum injection
to maximise column reconditioning and minimise carry-
over. For analysis, peaks 1 and 2 (formed as above) were
concentrated using 15mL capacity, 10kDa MWCO ﬁlters
(Sigma-Aldrich) for centrifugation at 4000g for 5–15min.
The concentrated material was then desalted (for MS) or
desalted and buffer exchanged into DIGE buffer (7M urea,
2M thiourea, 4% CHAPS) using 2mL 7kDa MWCO ZEBA
spin-desalting columns according to the manufacturer’s
instructions.
2.4 Top-down assessment of reproducibility,
speciﬁcity, and depth of coverage using
1-D SDS-PAGE and 2-D DIGE
Peak 1 material was combined from four runs of each
column to give sufﬁcient protein for downstream gel-based
analyses and a similar process was carried out for peak 2
material. Each such pool was considered as one replicate in
the experimental design (Fig. 1A).
2.4.1 1-D PAGE
Examination by 1-D PAGE as a gross assessment was
initially carried out. Both peak 1 (1mg protein/gel lane) and
peak 2 (5mg protein/gel lane) from four replicates were
subjected to separation by 1-D PAGE in 1816cm 12% gels
using the SE600X electrophoresis system (Hoeffer, MA,
USA) and subsequently silver stained using the Proteo-
Silver
TM Silver Stain Kit (Sigma-Aldrich), according to the
manufacturer’s instructions.
2.4.2 2-D DIGE
Two separate DIGE experiments were performed,
one comparing the peak 1 samples from all the immuno-
depletions, and one for the peak 2 samples. In each case,
an internal standard was used formed from equal
amounts of material from each replicate from each column.
Four replicates of peak 1 and peak 2 for each of the
three columns in DIGE-labelling buffer (7M urea, 2M
thiourea, and 4%w/v CHAPS) were adjusted to a protein
concentration of 1mg/mL for lysine DIGE labelling
with ﬂuorescent dyes Cy2, Cy3, or Cy5 (GE Healthcare).
Samples were buffered with 2.5mL of 1M Tris-HCl, pH 9.5,
per 50mg of protein to pH 8.5–9.5 estimated with pH-Fix
4.5–10 strips (Fisher Scientiﬁc, UK). Diluted Cy-dye (1:4 in
anhydrous DMF) was used to label samples in the ratio of
50mg protein:200pmol dye for 30min on ice. An aliquot of
10mM lysine (1ml/50mg labelled protein) was then added
and the sample was incubated on ice for 10min to allow
coupling to any unreacted dye. An equal volume of buffer
containing 7M urea, 2M thiourea, 4%w/v CHAPS, and
1.6%v/v Pharmalyte 3–10, 2%w/v DTT was then added to
each sample and the samples were incubated at room
temperature for 15min. Samples were combined with an
internal standard consisting of equal amounts of depleted
material from each column and an appropriate volume of a
buffer containing 7M urea, 2M thiourea, 4%w/v CHAPS,
0.8%v/v Pharmalyte 3–10, and 1%w/v DTT was added to
make a total volume of 450mL containing 75mg labelled
protein per dye/gel strip with 10mL 0.25%w/v bromophenol
blue added to colour the samples. IEF was performed on
24cm pH 3–10 non-linear gel strips using an Ettan
IPGphor
TM 3 (both from GE Healthcare). Active re-hydra-
tion at 30V for 18h was followed by the following
gradient program: 500V for 1h, gradient to 1kV over 5h
30min, gradient to 8kV over 3h, then 8kV for 14h (total
program time, 130kVh). After focussing, strips were incu-
bated for 15min with 10mL/strip of equilibration
buffer (6M urea, 30%v/v glycerol, 2%w/v SDS in 0.05M
Tris-HCl, pH 6.8) supplemented with 10mg/mL DTT,
followed by alkylation with 10mL equilibration buffer/strip
supplemented with 40mg/mL iodoacetamide (IAA).
Second-dimension separation was achieved using 24cm
10% polyacrylamide gels. Strips were placed on the gels and
overlayed with molten 1%w/v low-melting-point agarose
and electrophoresis carried out in an Ettan DALTtwelve
Separation Unit (GE Healthcare) tank at 1.5W/gel overnight
with 1 Tris-glycine running buffer (25mM Tris,
pH 8.3, 192mM glycine, 0.1%w/v SDS), and 2.5 Tris-
glycine running buffer above the gels. Gels were then
scanned on a Typhoon Trio (GE Healthcare) in ﬂuorescence
acquisition mode, using 1000 micron pixel size to test the
photomultiplier tube (PMT) voltage settings and 100 micron
pixel size for ﬁnal scans. Focal plane was set to 13mm, and
laser settings were selected to correspond to the dyes being
used. PMTs were adjusted to achieve intensity of 80–90000
in the spot used for normalisation (the second most abun-
dant spot on each gel). DIGE images were analysed using
Progenesis SameSpots V3.3 (Nonlinear Dynamics,
Newcastle-upon-Tyne, UK), being superceded later with V4
for the alignment of preparative gels and generation of spot-
picking lists.
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Preparative gels were generated as above but using 200mg
unlabelled protein for peak 1 material and 150mg unlabelled
protein for peak 2. Gels were as above, but were backed with
polyester backing (PAG backing – Lonza, UK) and were
silver stained using a modiﬁed form of the ProteoSilver
TM
method (lower percentage alcohol treatments) to minimise
gel volume alterations and avoid detaching of the gels from
the PAG backing. Picking list ﬁles were imported from
Progenesis SameSpots into the Ettan Spot Picker V1.2
software and gel spots (diameter, 1.4mm) were obtained
directly using the robotic spot picker into in a 96-well plate
in water. Gel pieces were equilibrated in 100mM ammo-
nium bicarbonate and then reduced/alkylated with DTT/
IAA, respectively, followed by incubation with 40ng/mL
sequencing grade-modiﬁed trypsin (activity 20388U/mg,
Promega) overnight. Supernatant from the overnight
digestion was collected into fresh tubes and the gel pieces
were extracted with water for 10min in a sonicating water
bath, followed by a repeat extraction for 10min with 50%v/v
ACN/1%v/v formic acid. Extraction was performed twice in
total and all the extracts were combined. The peptide extract
was frozen (201C), dried using a Speedvac, and the
samples were stored at 801C until analysis. Tryptic digests
were analysed by LC-MS/MS using a nano-HPLC (Agilent,
USA) QSTAR-XL quadrupole time-of-ﬂight hybrid mass
spectrometer (Applied Biosystems, UK) as described
previously [15], except that the LC/MS/MS raw data were
processed by Analyst v2.0 and a script plug-in Mascot.dll
1.6b24 (Applied Biosystems), and the MS/MS spectra were
sent to the local MASCOT database search engine (v2.2,
Matrix Science, UK) for database searching with the
following parameters: IPI human protein database (version
3.48, 71401 sequences); precursor mass tolerance, 0.15Da;
fragment ion mass tolerance, 0.1Da; enzyme, trypsin/P;
max missed cleavage site, 1; Peptides with scores above
identity level (po0.05) were considered identiﬁed. Protein
identiﬁcations required at least one unique signiﬁcant
peptide (po0.05) and were ﬁltered to remove keratins and
trypsin autolysis peptides.
2.5 Bottom-up assessment of protein removal and
depth of coverage using LTQ Orbitrap Velos
LC-MS/MS analysis
For the initial LC-MS/MS studies, each technical replicate
(prepared from pooled peak 1 material from four runs of
each column) or whole serum was analysed (three injections
per replicate) by LC-MS/MS following processing using the
Filter Aided Sample Preparation (FASP) method [16] as
follows. All centrifugation steps were performed at
14000g. In total, 250mg of each sample (132mg in the case
of Prot20 column) was heated at 951C with 50mM DTT,
centrifuged for 5min, and applied to a 30-kDa MWCO ﬁlter
(Amicon Ultra-0.5 Centrifugal Filter Unit with Ultracel-30
membrane, Millipore). The sample was washed on the ﬁlter
with 250mL of 50mM ammonium bicarbonate. Brieﬂy,
80mL of 120mM IAA was added to the ﬁlter and the
samples were incubated in the dark for 10min. After a
5-min centrifugation step, the sample was washed on the
ﬁlter four times with 250mL of 50mM ammonium bicar-
bonate. Porcine trypsin (activity 20388U/mg, Promega) was
re-suspended in 40mL 50mM ammonium bicarbonate and
8mL of this solution was added to each sample. After over-
night incubation with a fresh collection tube at 371C, ﬁlters
were washed with 40mL, then 100mL, water, and the ﬁltrate
was collected by centrifugation.
The samples were analysed twice, ﬁrst using a 4-h LC
gradient and then repeated using an extended 5-h gradient
(MARS14- and Prot20-depleted samples only) with three
injections for each sample in each case. For the ﬁrst runs, the
peptide mixture was separated by nanoscale C18 reversed-
phase LC (Easy-nLC, ThermoScientiﬁc, Bremen, Germany)
coupled on-line to an LTQ-Orbitrap Velos mass spectrometer
(ThermoScientiﬁc). An aliquot of 1mg material was loaded
onto a peptide captrap (Michrom Bioresources, Auburn, CA,
USA) using water containing 0.1% formic acid (mobile phase
A) at 10mL/min. Peptide separation was performed on a
pulled tip column (15cm100mm id) containing C18
reprosil 5mm particles (Nikkyo Technos, Tokyo, Japan) using
increasing amount of ACN containing 0.1% formic acid
(mobile phase B) at 300nL/min. Gradient conditions were as
follows: 5–34% B (0–210min), 34–50% B (5min), 50–80% B
(3min), 80% B held for 4min, 80–5% B (3min), and the total
run time was 240min. The mass spectrometer was operated
in positive ion mode and a data-dependent ‘Top 20’ method
was employed. In each cycle, a full-scan spectrum was
acquired in the Orbitrap at a target value of 1E6 ions
(2 microscans) with resolution R530000 at m/z 400
followed by ion-trap CID on the 20 most intense ions with a
target value of 5E3 ions (1 microscan). The ‘lock mass’
function was enabled for the MS mode, where the back-
ground ion at m/z 445.1200 was used as the lock mass ion.
General MS conditions were as follows: spray voltage,
1.75kV; no sheath or auxiliary gas ﬂow; S-lens, 60%. FT
preview mode was disabled, charge-state screening enabled,
and rejection of singly charged ions enabled. Ion selection
thresholds were 5000 counts for MS2, 35% normalised
collision energy, activation q50.25, and activation time of
10ms were applied for CID. Dynamic exclusion was
employed and 75ppm window of the selected m/z was
excluded for 20s. Samples were analysed in triplicate, and the
results were combined. The MASCOT program version
2.2.04 was used to generate up to ten peptide sequence
candidates per fragmentation spectrum (Matrix Science), and
International Protein Index (IPI) version 3.48 was searched.
For database searching, maximum peptide mass deviation
was 7ppm and m/z 0.5 units for fragmentation peaks (opti-
mal for linear ion-trap data). Data analysis was performed
using the MaxQuant software (version 1.0.13.13) [17].
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FDR at the protein level. Carbamidomethylation was set as a
ﬁxed modiﬁcation, with protein N-terminal acetylation and
oxidation of methionine as variable modiﬁcations, enzyme:
trypsin/P, maximum number of missed cleavages: 2. Inge-
nuity Pathways Analysis (IPA) software was used subse-
quently to analyse the location annotations for the protein
lists produced. Where multiple UniProt numbers were
associated with an entry on the IPI human 3.48 database, one
entry only was used for IPA analysis to avoid skewing data
using multiple accession numbers for non-unique peptides.
For the longer LC separation (5h), the peptide mixtures
were acidiﬁed to the ﬁnal 0.1% TFA concentration and 1mg
of peptides per each run was used. The LC-MS/MS analy-
tical setup was similar to that described previously [18]. The
LC setup was connected to LTQ Orbitrap Velos mass spec-
trometer equipped with a Proxeon nanoelectrospray ion
source. The samples were injected directly onto an in house
25cm capillary emitter column (75mm id, packed with
3.5mm Kromasil C18 media), using Dionex UltiMate 3000
RSLCnano system at a ﬂow rate of 0.5mL/min. The total
acquisition time was 300min, the major part of the gradient
(from 10 to 270min) being 3–25% ACN in 0.1% formic acid
at a ﬂow rate of 0.4mL/min. Data-dependent acquisition was
implemented. Survey MS scans were acquired in the Orbi-
trap with the resolution set to 60000. Up to 30 most intense
ions per scan were fragmented and analysed in the linear
trap. The data analysis was again performed using the
MaxQuant software [17].
2.6 Bottom-up assessment of reproducibility using
LTQ Orbitrap Velos LC-MS/MS analysis
Based on the results found, the MARS14 and Prot20
columns were then selected for the examination of repro-
ducibility by LC-MS/MS. This was carried out using a
similar pooled serum sample (protein concentration,
48.7mg/mL) with three independent (different days) tech-
nical replicates of the column depletion in each case
followed by analysis by LC-MS/MS as above using three
injections but with 4-h LC run for each injection (Fig. 1B).
Additionally, to be able to examine the reproducibility of the
LC-MS/MS per se, analysis of one replicate from each of the
columns was repeated on three separate occasions (three
separate analyses, three injections each time). The label-free
quantitation algorithm within the MaxQuant software
(version 1.1.1.21) was used.
3 Results
3.1 Recovery and initial reproducibility assessment
The amount of protein recovered in peak 1 decreased with
increasing immunodepletion of the serum pool (starting
protein concentration of 67.3mg/mL) as expected with mean
percentage recoveries of 11.2, 7.8, and 4.5% for MARS6,
MARS14, and Prot20, respectively for 24, 24, and 16 runs
and corresponding CVs of 6.0% for MARS6, 10% for
MARS14 but increasing to 16% for Prot20. Two blank runs
were necessary to minimise carry-over for the MARS6
column, and one for the MARS14 and Prot20 columns.
Reproducibility of the immunodepletion procedure at a
gross level was assessed by examination of the UV absorp-
tion traces and 1-D SDS-PAGE (Supporting Information
Figs. 1 and 2) which demonstrated good reproducibility.
Reproducibility was also assessed using 2-D DIGE for peaks
1 and 2 by examining the CVs of spot-normalised volumes
for each peak and each column (24 gels i.e. four replicates in
each case; Supporting Information Fig. 3). Distributions of
CVs for protein spot intensities with the peak 1 and peak 2
2-D DIGE gels were all positively skewed. Median CVs were
similar across all three columns at 26.4% (MARS6), 28.4%
(MARS14), 25.3% (Prot20) for depleted (peak 1) material,
and 28.5% (MARS6), 36.2% (MARS14), 31.1% (Prot20) for
bound (peak 2) material.
3.2 2-D DIGE analysis of the depleted material
Distinct gel proﬁles were seen for each column type
(Supporting Information Fig. 4). Standard DIGE experi-
mental analysis was performed within the Progenesis
SameSpots software, including selection of reference image,
alignment, and editing. Column speciﬁc sub-experiments
were also created where each spot could be assessed for
inclusion looking only at that column class (MARS6,
MARS14, or Prot20), using aligned DIGE images from the
main experimental analyses, to facilitate spot counting. For
the depleted material (peak 1), this gave 1186 spots
(MARS6), 1137 spots (MARS14), and 1149 (Prot20). For the
bound material (peak 2), this gave 750 spots (MARS6), 919
spots (MARS14), and 969 spots (Prot20).
PCA using only those spots with signiﬁcant differences
between groups by ANOVA with po0.05 showed good
separation between columns for both peak 1 and peak 2
experiments, indicating that the proﬁle continues to
alter with increasing immunodepletion as expected
(Supporting Information Fig. 4). The ﬁrst two principal
components explained approximately 75% of the total
variation in the data.
A spot classiﬁcation dendrogram was used to identify
peak 1 spots which were signiﬁcantly different between (i)
MARS6 and all other groups; (ii) MARS14 and all other
groups; (iii) Prot20 and all other groups; (iv) MARS6 and
MARS14; (v) MARS14 and Prot20; (vi) MARS6 and Prot20;
and (vii) spots displaying stepwise increase with increasing
immunodepletion. A cut-off of Z4-fold change in the
direction of increasing immunodepletion was used to create
lists of spots of interest from these groups resulting in a
non-redundant list of 123 spots. Following manual quality
Proteomics 2011, 11, 2222–2235 2227
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for sequencing (Supporting Information Fig. 5a). However,
none of these was found to be of signiﬁcantly lower abun-
dance or major potential interest with many representing
additional isoforms of previously visualised proteins
(Supporting Information Data 1, Supporting Information
Data 4, and single peptide spectra are available at
www.proteomics.leeds.ac.uk/supplementary_data/immuno-
depletion).
3.3 Speciﬁcity of the immunodepletion
Speciﬁcity was assessed on the basis of DIGE proﬁles of peak
2 proteins essentially as described above for peak 1. Non-
redundant lists of proteins appearing sequentially with each
depletion were produced but given the number of spots it was
not possible to sequence all proteins. Publicly available 2-D
PAGE maps of human serum and plasma were used to
potentially identify the locations of those proteins expected to
be present based on the columns used and these spots were
also added to this list for potential-sequencing conﬁrmation.
A total of 87 protein spots were selected for sequencing
following quality control (Supporting Information Fig. 5b).
Identiﬁcations were consistent with the respective column
depletions in all cases (Supporting Information Data 4, and
single peptide spectra are available at www.proteomics.
leeds.ac.uk/supplementary_data/immunodepletion).
3.4 Efﬁciency of high-abundance protein removal by
the immunodepletion columns
In the peak 1 DIGE gels, among the spots cut in analysing
signiﬁcant changes, tryptic peptides compatible with
immunoglobulin light and heavy chains, albumin, a1-anti-
trypsin (all columns), and a2-macroglobulin and a1-acid
glycoprotein-1 (MARS14 and Prot20) were observed, indi-
cating incomplete removal. LC-MS/MS analysis of peak 1
material also revealed evidence for the presence of all the
depleted proteins at the Z2 peptide/protein level within the
peak 1 samples with the exception of transferrin for the
MARS6 column (not seen at even the single peptide level)
and transthyretin for the MARS14 column which were not
detected. It was very evident, however, that even when
proteins which were nominally depleted were detected, the
number of peptides found was much reduced compared
with those found in the whole-serum sample (Supporting
Information Data 2 and 3).
3.5 Depth of serum proteomic coverage within
peak 1 samples assessed by LTQ Orbitrap Velos
LC-MS/MS
The total number of protein identiﬁcations found within
each immunodepleted sample increased with each increas-
ing degree of immunodepletion (Table 1), for example from
159 (266) in whole serum to 301 (442) with Prot20 at the Z2
(Z1) unique peptide levels, respectively. Full details of the
protein/peptide identiﬁcations observed are provided in
Supporting Information Data 5. Considerable overlap was
observed between intact serum and the three different
immunodepleted samples in terms of the proteins observed
(Fig. 2); however, both the MARS14 and PROT20 peak 1
samples contained substantial numbers of identities found
only in those samples – 19 proteins in MARS 14 peak 1, and
57 proteins in Prot20 peak 1 at the level of two signiﬁcant
Table 1. Protein identiﬁcations observed within the immunodepleted peak 1 samples and the whole-serum pool when using the LTQ-
Orbitrap Velos at the 1 and Z2 unique peptide levels, with either 4 or 5h LC-MS/MS runs, and with three injections per sample
Sample Identiﬁcations (4h run) Identiﬁcations found
only in that
Identiﬁcations (5h run)
1 Unique
peptide
Z2 Unique
peptides
Total sample (2 unique
peptides, 4h run)
1 Unique
peptide
Z2 Unique
peptides
Total
Whole-serum pool 107 159 266 14 N/A N/A N/A
MARS6 peak 1 127 234 361 5 N/A N/A N/A
MARS14 peak 1 133 272 405 19 126 306 432
Prot20 peak 1 141 301 442 57 115 311 426
Figure 2. Venn diagram of protein identiﬁcations from the 1-D
LC-MS/MS LTQ-Orbitrap analysis at Z2 unique peptides.
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(Prot20) if single peptide results were also included). When
the MARS14 and Prot20 columns were further compared in
the detailed reproducibility study, similar ﬁndings were
obtained with a high level of overlap and 35 proteins being
found only with the Prot20 column at the Z2 peptide level
(18 at the 11 level), and 29 proteins were found only with
the MARS14 (33 at the 11 level).
Analysis of the origin of the proteins using IPA demon-
strated a progressive increase with increasing immunode-
pletion in the number of proteins in peak 1 with a predicted
cytoplasmic/plasma membrane localisation and a conco-
mitant decrease in the number of extracellular proteins
(Fig. 3) which was similar for all MS analyses. Many
examples illustrate that an increasing degree of immuno-
depletion coupled with high mass accuracy MS with only a
single LC step can begin to enable the detection of moderate
to lower abundance proteins (Table 2) such as NGAL,
pyruvate kinase M1/M2, carbonic anhydrase III (MARS14
only) interleukin 1 (IL-1) receptor-like protein, carbonic
anhydrase I and II, SPARC/osteonectin (MARS14 and
Prot20), IL-6 receptor subunit b, macrophage CSF 1 recep-
tor, fatty acid-binding protein 4, vinculin (Prot20 only), and
transforming growth factor b receptor (Prot20 only, 11
peptide level, MS spectrum supplied at www.proteomics.
leeds.ac.uk/supplementary_data/immunodepletion).
The extended (5h LC) analysis of depleted MARS14 and
Prot20 samples showed considerable overlap – approxi-
mately 92% of the identities for the MARS14 sample were
found in the second analysis, and 87% for the Prot20 sample
with further identiﬁcations including osteopontin,
cystatin-M (MARS14 only), and mast/stem cell growth
factor receptor (Prot20 only). In the MARS14 peak 1 sample,
proteins found previously in the 20 depleted samples with
4-h LC run were also found with MARS14 depletion such as
inducible T-cell co-stimulator ligand, IL-1 receptor accessory
protein, cell adhesion molecule 1, and lysozyme C
(Supporting Information Data 5).
3.6 Detailed reproducibility assessment (MARS14,
Prot 20, and 1-D LC-MS/MS)
Reproducibility of the LC-MS/MS aspect examined by repeat
analysis of a single sample three times (three injections each
repeat) was excellent in terms of proteins identiﬁed with 300
and 292 proteins being present in all repeats from a total
of 353 and 347 for MARS14 and Prot20, respectively
(Fig. 4A). The number of proteins found between replicate
immunodepletion column11-D LC-MS/MS runs was
also remarkably consistent with mean (SD) of 292 (3) and
290 (5), respectively, at the Z2 unique peptide level and a
high degree of overlap in terms of protein identities
(Fig. 4B). Similarly, in terms of quantiﬁcation, the exam-
ination of the distribution of %CVs for the normalised
intensity for each observed protein showed similar skewed
plots as expected for both column samples with 50th, 75th,
and 90th quantiles of 14.52, 33.44, and 90.7%, respectively,
for the MARS14 peak 1 sample, for example (Fig. 5A).
Examination of the reproducibility of each immunodeple-
tion column superimposed on the LC-LTQ Orbitrap Velos
process showed only minor to moderate increases in the
%CV at each quantile (Fig. 5B), for example 18.21, 47.19,
and 97.96% as a comparison to the ﬁgures above, showing
Figure 3. Predicted localisation of proteins identiﬁed in the peak 1 immunodepleted material by LTQ Orbitrap Velos analysis. Localisation
predictions were obtained from IPA (A) at the Z2 unique peptide level and (B) at one unique peptide level. Total identiﬁcations at the
relevant peptide level are given under each pie chart.
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process. However, the 50th, 75th, and 90th quantiles are
clearly lower for the MARS14 LC-MS/MS compared with
the Prot20 (e.g. 50th quantile 18.21% for MARS14 versus
30.92% for Prot20). Full details are provided in Supporting
Information Data 5.
The data from the reproducibility experiment were also
analysed in terms of determining appropriate thresholds for
future comparative experiments, which could then be used
to identify potential biological differences, i.e. changes
outside the limit of the technical variability of the process.
By plotting the ratio of observed protein intensities against
the total intensity in every possible pair of runs (and the
reversed pairs for symmetry), scatter plots of the technical
variation in ratios (fold changes) can be created (Fig. 5C).
While the overall shape of the distributions is the same for
both columns, the required ratio as a threshold for the
detection of a biological difference would be greater for the
Prot2011-D LC-MS/MS process than for the MARS1411-D
LC-MS/MS process. This is particularly notable at low total
intensities.
4 Discussion
Immunodepletion is an attractive fractionation strategy for
clinical ﬂuid-based biomarker discovery pipelines and in
this systematic approach we demonstrate that as a relatively
simple and reproducible ﬁrst step prior to single-dimension
LC-MS/MS with the LTQ Oribtrap Velos, low- to moderate-
abundance proteins can be found including many proteins
of potential biological relevance in this speciﬁc disease
situation. Such a strategy is compatible with biomarker
studies comparing multiple samples in a relatively high-
throughput comparison. However, immunodepletion
coupled with 2-D DIGE as the downstream analysis is not as
beneﬁcial. Distinct proﬁles with good separation on PCA are
readily apparent, but far fewer proteins of interest were
revealed with increasing immunodepletion and although
additional proteins are found, many represent additional
isoforms of more abundant proteins found without immu-
nodepletion. While immunodepletion of eight abundant
serum proteins combined with anion-exchange and size-
exclusion chromatography has resulted in the detection of
some lower abundance molecules (e.g. cathepsins) using
2-D PAGE [19], other 2-D gel-based studies have reported
relatively small improvements in being able to visualise
lower abundance proteins after immunodepletion [20]. For
example, in a study using 2-D DIGE analysis of sera from
normal controls and patients with lung cancer following
depletion of the 6 most abundant proteins 14 proteins were
observed to alter in a statistically signiﬁcant manner;
however, the majority of the proteins identiﬁed were forms
of haptoglobin or apolipoproteins [21]. This was also found
to be the case when immunodepleted samples were
subjected to more extensive fractionation based on solution-
phase IEF fractionation and narrow range IPG strips prior
to 2-D PAGE [22].
Importantly, acceptable reproducibility was observed for
all the columns as assessed at a gross level by HPLC/FPLC
absorption traces, 1-D gel appearance, and protein recov-
eries, but also by examining CVs of spot normalised
volumes on 2-D DIGE gels. Other investigators have reached
similar conclusions for various immunodepletion columns
Figure 4. Venn diagrams of protein identiﬁ-
cations from the detailed assessment of
reproducibility, where each identity is based
on Z2 unique peptides. (A) In each case
(MARS14 and Prot20), a depleted sample has
been analysed three times through 1-D
LC-MS/MS on the LTQ Orbitrap Velos (three
injections per each analysis run); (B) In each
case (MARS14 and Prot20), a sample has
been depleted in three separate replicates of
each column, each of which has been
analysed by 1-D LC-MS/MS on the LTQ
Orbitrap Velos (three injections per run).
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methodologies e.g. SELDI-TOF-MS [8]. Both MARS14 and
Prot20 performed reproducibly in terms of the overlap
between protein identities observed and also in a detailed
analysis of the technical quantitative variability using label-
free analysis where it was apparent that the MARS14
column demonstrated less variability than the Prot20 and
contributed only a low to moderate increase to the variability
of the LC-MS/MS process itself. It was also very apparent
that the differences in precision depended on the abun-
dances of the proteins detected, which should be an
important consideration when designing and interpreting
comparative studies. Similarly, a comparison of MARS6
columns with eight other methods of serum fractionation
including size fractionation and Protein A/G separation
previously found the MARS6 immunodepletion to be the
most reproducible with median CVs of feature intensity
values of approximately 11% [6], which at least in part was
related to the more automated process with this column
compared with the other approaches.
Speciﬁcity of depletion as assessed by 2-D DIGE was good
as although >700 spots were found in peak 2 fractions for
each immunodepletion, many are multiple forms of the
targeted proteins. While all proteins sequenced in our study
were compatible with expected depletions, this may not be
the case for all spots observed as this was a cross-sectional
sample rather than a reference map. Concomitant removal of
unintended proteins using a MARS6 column has been
reported by others [11], and using more sensitive 1- or 2-D
LC-MS/MS analyses, multiple non-target proteins have been
found to bind to several immunodepletion columns
[10, 24–27]. This may be direct non-speciﬁc binding, but
Figure 5. (A) 1-D LC-MS/MS (LTQ Orbitrap Velos) reproducibility – histograms of the CVs of normalised intensities for observed proteins in
three repeated analyses (three injections per run) for one depleted peak 1 MARS14 sample and one depleted peak 1 Prot20 sample; (B)
Reproducibility of each column plus 1-D LC-MS/MS process as a whole – histograms of the CVs of normalised intensities for observed
proteins identiﬁed through the whole immunodepletion column plus 1-D LC-MS/MS process (for each of MARS14 and Prot20) in three
technical replicates of the whole process; (C) Scatter plots of log10(intensity) versus log2(ratio) for proteins in every possible pair of
analyses within the repeated LC-MS/MS analysis for peak 1 samples from MARS14 and Prot20 columns. Dotted horizontal lines represent
different ratios as labelled (1/).
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proteins bind to albumin, for example prostate-speciﬁc anti-
gen, glycosylasparaginase, and ryanodine receptor 2 [28].
Conversely, by 2-D DIGE, proteins intended to be depleted
appeared to be absent from inspection of the gels, but on the
analysis by LC-MS/MS, depletion, although very high, was
not absolute. Similar results were observed in other LC-MS/
MS studies using immunodepletion columns [7, 10, 13,
24–27] and also using ELISA [23] where depletion efﬁciency
was found to be 499%, even with some deterioration of IgG
and IgA depletion over time. Similar protein-speciﬁc differ-
ences in efﬁciency have been reported for the MARS14
column by LC-MS/MS with a1-acid glycoprotein, a2-macro-
globulin, complement C3, and apolipoproteins being the least
efﬁcient [10] although we found C3 and a1-acid glycoprotein
to be removed more efﬁciently. What is very important,
however, is the consistency of the speciﬁc and non-speciﬁc
protein removal/depletion [10, 25, 26] enabling such
approaches to be used in a fractionation scheme.
Although speciﬁcity is important and reproducibility
even more so, improvements in numbers of proteins iden-
tiﬁed and depth of coverage is critical. The numbers of
serum proteins detected in the current study, given that it is
only based on a single-dimensional LC-MS/MS approach,
are impressive. This can be contrasted with the lower
numbers previously reported for the analysis of serum
samples using much more time-consuming extensive and
expensive LC/LC-based peptide separation prior to techni-
ques such as iTRAQ, for example. iTRAQ-based comparison
of serum samples from normal healthy controls, patients
with pancreatic cancer, chronic pancreatitis, and biliary
obstruction following removal of the 20 most abundant
serum proteins resulted in the identiﬁcation of 217 proteins
[29]. Similarly, immunodepletion of serum from ovarian
cancer patients with either the IgY12 HPLC column, the
IgY12 spin column, or the MARS6 column combined with
LC/LC-MS/MS iTRAQ analysis identiﬁed 220 different
proteins with a 95% conﬁdence level across the three
different immunodepletion strategies [30]. Other studies
examining single samples with extensive fractionation
through multidimensional LC-MS/MS have reported much
greater numbers but not in quantitative comparative studies
[25, 27] and even then we have detected some of the lower
abundance proteins they describe.
Importantly, we detected a clear trend in increasing
protein identiﬁcations and increased representation of
membrane and intracellular proteins, with increasing
immunodepletion. Furthermore, the identiﬁcations found
with increasing immunodepletion demonstrated proof of
principle in that low to moderate concentration and known
renal biomarker molecules were detected, e.g. FABP4 and
NGAL which is of major current interest as a renal injury
biomarker [31]. Using pathological sample pools rather than
samples from normal healthy controls in contrast to many
immunodepletion evaluation studies [6, 10, 26–28] has really
allowed us to evaluate the potential ability of immunode-
pletion and LC-MS/MS analysis in detecting some of the
low- to moderate-abundance molecules which may only be
present in disease. The number and nature of these iden-
tiﬁcations is in keeping with lower abundance protein
detection after immunodepletion [11, 26, 27] but in contrast
to the limited improvement found in some other studies
[14]. The relationship between likely clinical utility and
abundance of proteins is difﬁcult and many existing
biomarkers lie in the nanogram per milliliter concentration
range. Tu et al. [11] argue that their detection of only 23 low-
abundance proteins in the o10ng/mL range (5–6% of their
total protein identiﬁcations) means low-abundance proteins
are likely to remain undetected following MARS7 or
MARS14 depletion. However, consideration should be given
to the nature of the identiﬁcations and their potential rele-
vance as biomarkers, rather than simply the proportion of
the identiﬁcations they make up and their study was carried
out using samples from healthy donors where many
proteins present at low abundance even in disease may not
be present. Examples from the proteins found only with the
more extensive depletions in our study include a number of
plausibly relevant molecules for the clinical context from
which the serum pool was derived, e.g. IL-1 receptor
accessory protein, TGF-b receptor 2, IL-6 receptor subunit b,
and macrophage CSF-1 receptor. The ability of the process
used here to detect low-concentration proteins of interest is
likely to be partly attributable to the use of the high
mass accuracy Orbitrap Velos as the downstream analysis
platform where even with LC-MS/MS, depth of coverage is
superior to that found with much more extensive and time-
consuming multidimensional LC-MS/MS approaches in
some studies.
Whilst we have focused largely on Z2 unique peptide-
based identiﬁcations, information on the numbers of iden-
tities at the one unique peptide level (Table 1), as well as
their localisation by IPA analysis (Fig. 3B) is also included.
The use of higher mass accuracy MS does increase conﬁ-
dence in such identiﬁcations although the issue of the use of
single peptide-based identiﬁcation is under debate [32, 33].
These qualitative data are provided to illustrate the possible
depth of coverage, and to allow comparison with other data
sets. Clearly, any identiﬁcation at the one unique peptide
level would require further conﬁrmation.
These results support the use of the greater levels of
immunodepletion (14 or 20 abundant proteins) in poten-
tially revealing biomarker candidates in serum-based clinical
discovery experiments when coupled with relatively high-
throughput but high mass accuracy LC-MS/MS. Although
signiﬁcant improvements were found with these columns
compared with depleting only six proteins, the difference
was less apparent moving from depleting 14 to 20 proteins
(though further large increases in depletion may be expected
to result in even greater depth of coverage, for example
depletion of 60 protein [26]). Under such conditions,
acceptable reproducibility can be achieved and detection of
tissue- and cell-derived products arising from, for example,
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automation and lower ﬁnal volume yield aspects) and better
reproducibility, we are now systematically exploring the
potential of depleting 14 proteins in carefully designed
comparative studies, addressing speciﬁc clinical questions to
determine to what level new markers can now be discovered
using this approach, before consideration of further frac-
tionation strategies in the future.
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